Correlation between Pre Biopsy Serum Prostate Specific Antigen Level and Gleason Score in Patients Diagnosed with Prostate Adenocarcinoma: A Hospital Based Study
Antigen Level and Gleason Score in Prostate Adenocarcinoma
DOI:
https://doi.org/10.54393/pjhs.v3i07.404Keywords:
Prostate Specific Antigen, Gleason Score, Prostate AdenocarcinomaAbstract
Prostate Specific Antigen (PSA) is a non-invasive biomarker in the management of prostate adenocarcinoma. Due to its low specificity, its diagnostic role is controversial in prostate adenocarcinoma. Gleason score is considered as most powerful predictor of prostate carcinoma. PSA in combination with Gleason grading system improves the detection of pathological stage of prostate adenocarcinoma. Objective: To determine the degree of correlation between pre biopsy serum PSA level and Gleason score in patients diagnosed with prostate adenocarcinoma. Methods: Retrospective cross sectional study was conducted in Chemical Pathology and Histopathology department, Sheikh Zayed Hospital, Rahim Yar Khan between July 1, 2021 and September 31, 2022. A total of 51 histopathologically confirmed cases of prostate adenocarcinoma with documented Pre biopsy PSA level and Gleason score were included in the study. Serum PSA level correlation is compared with Gleason score, Gleason Pattern and Gleason Grade. p-value ≤0.05 taken as significant. Results: Mean age for prostate carcinoma patients was 65.71±10.062 years. Mean pre biopsy serum PSA level in study subjects was 40.31±37.52ng/ml. Of the total 51 study subjects, 27 (52.94%) were having Gleason score 7 suggestive of moderately differentiated tumor. Among these, 15(55.6%) were having serum PSA level between 10.01-50.00ng/ml. Statistically significant good correlation of serum PSA with Gleason score, Gleason pattern and Grade was established with p value <0.05. Conclusion: It was concluded that there is good degree of positive correlation between pre biopsy PSA level and Gleason score in patients with Prostate adenocarcinoma
References
Udoh EA, David DE, Eyo AE. Relationship between Serum Prostate Specific Antigen (PSA) and Gleason Score in Patients Diagnosed with Prostate Cancer. A Hospital Based Study.2020 Feb; 2(2): 47-53 doi: 10.36349/EASJMS.2020.v02i02.008
Bashir M. N. Epidemiology of prostate cancer. Asian Pacific journal of cancer prevention. 2015, 16 (13), 5137-5141
Antony T, Talwar R, Thomas T, Trehan V, Manwantkar S, Mohan H,et al. Correlation of serum prostate specific antigen with clinical, radiological and pathological variables in patients with prostate enlargement. International Surgery Journal. 2019 Nov; 6(12): 4408-14. doi: 10.18203/2349-2902.isj20195403
Cary KC, Cooperberg MR. Biomarkers in prostate cancer surveillance and screening: past, present, and future. Therapeutic advances in urology. 2013 Dec; 5(6): 318-29. doi: 10.1177/1756287213495915
O’Shaughnessy M, Konety B, Warlick C. Prostate cancer screening: issues and controversies. Minnesota medicine, 2010, 93(8)39-44
Elshahmi E, Emaetig F, Elgaraboli F, Abushnaf A, Alqawi O. The Evaluation of PSA levels in Libya Prostate Cancer Patients. Clinical Oncology Research and Reports. 2022, 3(1); doi: 10.31579/2693-4787/029
Ngwu PE, Achor GO, Eziefule VU, Orji JI, Alozie FT. Correlation between prostate specific antigen and prostate biopsy Gleason score. Annals of Health Research. 2019 Dec; 5(2): 243-8. doi: 10.30442/ahr.0502-26-56
Egevad L, Delahunt B, Srigley JR, Samaratunga H. International Society of Urological Pathology (ISUP) grading of prostate cancer–An ISUP consensus on contemporary grading. Apmis. 2016 Jun; 124(6): 433-5. doi: 10.1111/apm.12533
Shariat SF, Canto EI, Kattan MW, Slawin KM. Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Reviews in Urology. 2004; 6(2): 58-72.
Egevad L, Delahunt B, Srigley JR, Samaratunga H. International Society of Urological Pathology (ISUP) grading of prostate cancer - An ISUP consensus on contemporary grading. APMIS. 2016 Jun; 124(6): 433-5. doi: 10.1111/apm.12533
Okolo CA, Akinosun OM, Shittu OB, Olapade-Olaopa EO, Okeke LI, Akang EE, Ogunbiyi JO. Correlation of serum PSA and Gleason Score in Nigerian men with prostate cancer. African Journal of Urology. 2008 Mar; 14(1): 15-22.doi: 10.1007/BF02994508
Temel MC, Ediz C, Akan S, Ozer E, Yilmaz O. Association of Gleason score with PSA Values and Serum Testosterone Levels Measured Prior to Prostate Biopsy. Journal of College of Physicians and Surgeons Pakistan. 2020; 30(04): 399-402. Doi : doi: 10.29271/jcpsp.2020.04.399.
Lojanapiwat B, Anutrakulchai W, Chongruksut W, Udomphot C. Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice. Prostate international. 2014 Sep; 2(3): 133-9. doi: 10.12954/PI.14054.
Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, et al. Prostate‐specific antigen velocity and prostate cancer gleason grade and stage. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2007 Apr; 109(8): 1689-95. doi: 10.1002/cncr.22558
Iwamoto H, Izumi K, Kadono Y, Mizokami A. Prognosis of patients with prostate cancer and middle range prostate-specific antigen levels of 20–100 ng/mL. International Brazilian Journal of Urology. 2019 Jan; 45: 61-7. doi: 10.1590/S1677- 5538.IBJU.2018.0143
Goldberg H, Baniel J, Yossepowitch O. Defining high-risk prostate cancer. Current opinion in urology. 2013 Jul; 23(4): 337-41. 10.1097/MOU.0b013e328361dba6
Izumi K, Ikeda H, Maolake A, Machioka K, Nohara T, Narimoto K, et al. The relationship between prostate‐specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate‐specific antigen levels. The Prostate. 2015 Jul; 75(10): 1034-42. doi: 10.1002/pros.22985
Mašić S, Pezelj I, Krušlin B Prostate-Specific Antigen (PSA) Values in Patients with Low- and High-Risk Prostatic Adenocarcinoma. 2019 Nov; 58(Supplement 2): 12-5. doi: 10.20471/acc.2019.58.s2.02.
Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 1994; 43: 649–59. doi: 10.1016/0090-4295(94)90180-5
Bantis A and Grammaticos P. Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased?. Hellenic journal of nuclear medicine. 2012 Sep; 15(3): 241-6.
Moslehi M, Cheki M, Salehi-Marzijarani M, Amuchástegui T, Gholamrezanezhad A. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition). 2013 Sep; 32(5): 286-9. doi: 10.1016/j.remn.2013.01.002.
Kamel MH, Khalil MI, Alobuia WM, Su J, Davis R. Incidence of metastasis and prostate-specific antigen levels at diagnosis in Gleason 3+ 4 versus 4+ 3 prostate cancer. Urology Annals. 2018 Apr; 10(2): 203. doi: 10.4103/UA.UA_124_17
Aihara M, Lebovitz RM, Wheeler TM, Kinner BM, Ohori M, Scardino PT. Prostate specific antigen and Gleason grade: an immunohistochemical study of prostate cancer. The Journal of urology. 1994 Jun; 151(6): 1558-64. doi: 10.1016/s0022-5347(17)35302-8
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
